Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Neurofibromatosis 1 4Neurofibroma, Plexiform 2Neoplasms 2Pancreatic Neoplasms 1Pain 1Neurofibrosarcoma 1Melanoma 1Lung Neoplasms 1Kidney Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Oxaliplatin 9Leucovorin 8Fluorouracil 8Bevacizumab 6Cetuximab 5Specimen Handling 4fludarabine 3Pemetrexed 3Nivolumab 3Magnetic Resonance Spectroscopy 3Cyclophosphamide 3pembrolizumab 2encorafenib 2dehydroftorafur 2aldesleukin 2Irinotecan 2Immunoglobulin G 2Gemcitabine 2Folfox protocol 2Disulfides 2Cisplatin 2Celecoxib 2Carboplatin 2ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1temsirolimus 1sapanisertib 1repotrectinib 1relatlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colonic Neoplasms × AZD 6244 × 30 days × Clear all
NCT00600496 2026-05-27

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

AstraZeneca

Phase 1 Completed
140 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡